Brown Christopher Nigel 4
4 · Nexvet Biopharma plc · Filed Aug 2, 2017
Insider Transaction Report
Form 4
Brown Christopher Nigel
Director
Transactions
- Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−7,200$48,384→ 0 total - Disposition to Issuer
Options to purchase ordinary shares
2017-07-31$6.59/sh−7,080$46,693→ 0 totalExercise: $0.13Exp: 2020-11-05→ Ordinary Shares (7,080 underlying) - Disposition to Issuer
Options to purchase ordinary shares
2017-07-31$6.59/sh−3,600$23,742→ 0 totalExercise: $0.13Exp: 2019-07-01→ Ordinary Shares (3,600 underlying) - Disposition to Issuer
Ordinary Shares
2017-07-31$6.72/sh−8,800$59,136→ 0 total(indirect: Elsing Pty Ltd.)
Footnotes (4)
- [F1]Disposed of pursuant to a transaction agreement between the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired the Issuer.
- [F2]The reporting person has sole voting and dispositive power with respect to these reported securities.
- [F3]This option, which was fully vested, was cancelled in the Acquisition in exchange for a cash payment equal to $23,742.00, representing the difference between the exercise price of $0.125 per share and the $6.72 consideration per share payable in connection with in the Acquisition multiplied by the number of shares issuable on exercise of the option.
- [F4]This option, which was fully vested, was cancelled in the Acquisition in exchange for a cash payment equal to $46,692.60, representing the difference between the exercise price of $0.125 per share and the $6.72 consideration per share payable in connection with in the Acquisition multiplied by the number of shares issuable on exercise of the option.